Increased expression of claudin-17 promotes a malignant phenotype in hepatocyte via Tyk2/Stat3 signaling and is associated with poor prognosis in patients with hepatocellular carcinoma

Table 1 Expression of CLDN17 and the clinicopathological characteristics in HCC patients

Item	n	CLDN17 (+)	CLDN17 (−)	P
HCC tissues	52	28	24	< 0.01*
Hepatic tissues	30	12	18
Age (years)
≤ 60	21	11	10	1.000
> 60	31	17	14
HbsAg
+	42	23	19	1.000
-	10	5	5
Cirrhosis
+	34	18	16	1.000
-	18	10	8
Occurrence and metastasis
+	17	13	4	< 0.01*
-	35	15	20
Serum AFP (ng/ml)
< 400	22	13	9	0.637
> 400	30	15	15
TNM stage (AJCC)
I~II	27	17	10	< 0.01*
III~IV	25	11	14
Histological grade
Well-differentiated	24	15	9	< 0.01*
Moderately and poorly differentiated	28	13	15

^*Statistical significance was found with the Chi-square test/Chi-Square Goodness-of-Fit Test

ISSN: 1746-1596